資源描述：
《納米金表阿霉素復(fù)合體的體外抗腫瘤作用》由會員上傳分享，免費在線閱讀，更多相關(guān)內(nèi)容在應(yīng)用文檔-天天文庫。
1、納米金-表阿霉素復(fù)合體的體外抗腫瘤作用趙曉旭潘運龍胡楊志覃莉丁暉巫青【摘要】【目的】觀察納米金-表阿霉素復(fù)合體(EPI-AuNP)能否抑制人臍靜脈內(nèi)皮細胞(HUVEC)?人肝癌細胞(HepG2)的增殖?【方法】采用化學(xué)合成法制備EPI-AuNP,通過紫外-可見吸收光譜?熒光淬滅實驗?動態(tài)光散射及Zeta電位變化對其進行鑒定?體外實驗分為AuNP處理組?EPI處理組?EPI-AuNP處理組和空白對照組?將HUVEC?HepG2細胞分別接種于96孔板,培養(yǎng)24h后各組分別加入AuNP溶液?EPI溶液?EPI-
2、AuNP溶液和無血清培養(yǎng)液200μL,繼續(xù)培養(yǎng)24h后:MTT比色法檢測HUVEC?HepG2細胞生存率;紫外-可見分光光度法檢測各細胞內(nèi)EPI的積聚量?【結(jié)果】紫外-可見吸收光譜顯示:AuNP的最大吸收峰在520nm處,而EPI-AuNP在525nm處?EPI(100mg/L)熒光強度為195.2±7.5;EPI-AuNP為16.4±5.0,P=0.000?AuNP的平均粒徑及Zeta電位分別為:(14.34±0.75)nm?(-21.19±0.64)mV;EPI-AuNP為:(18.54±1.84)n
3、m?(-15.34±0.72)mV,P<0.01?體外實驗:MTT比色法結(jié)果顯示EPI處理組HUVEC?HepG2細胞的生存率分別為(29.25±1.59)%?(71.10±4.16)%;EPI-AuNP處理組:(21.29±1.51)%?(43.82±2.21)%,P=0.000?【結(jié)論】成功合成EPI-AuNP復(fù)合體,體外實驗證實其對HUVEC?HepG2細胞均具有增殖抑制作用?【關(guān)鍵詞】納米金-表阿霉素復(fù)合體;HUVEC;HepG2細胞22 Abstract:【Objective】Toobs
4、ervetheinvitroantitumoreffectsofepirubicin-nanogoldcompounds(EPI-AuNP).【Methods】EPI-AuNPwaspreparedbychemosynthesisandinvestigatedusingUV-Visspectrophotometer,fluorescencestudies,dynamiclightscattering,andzetapotential.Humanumbilicalveinendothelialcells(H
5、UVEC)andHepG2cellsweredividedinto4groups:AuNPtreatmentgroup,EPItreatmentgroup,EPI-AuNPtreatmentgroupandcontrolgroup.Afterseededin96-wellplateandculturedfor24hseparately,HUVECandHepG2cellsweretreatedwith200μLofAuNP,EPI,EPI-AuNP,andserum-freemedium,respecti
6、vely.InhibitioneffectofeachgroupontheHUVECandHepG2cellswasassessedusingMTTcolorimetricmethod.UV-Visspectrophotometerwasappliedtodetectthecellsepirubicinaccumulationofdifferentgroups.【Results】AredshiftintheSPRbandmaximaintheEPI-AuNPspectrum(λmax~525nm)asco
7、mparedwiththespectrumofAuNPalone(λmax~520nm);ThefluorescenceintensityofEPI(100mg/L)was(195.2±7.5)andEPI-AuNPwas(16.4±5.0),P=0.000.ThehydrodynamicdiameterofAuNPwas(14.34±0.75)nmwhileEPI-AuNPwas(18.54±1.84)nm.Meanwhile,thezetapotentialofAuNPwas(-21.19±0.64)
8、mVwhileEPI-AuNP22was(-15.34±0.72)mV,P<0.01.TheHUVECsurvivalrateofEPI-AuNPtreatmentgroup[(21.29±1.51)%]waslowerthantheEPIgroup[(29.25±1.59)%].TheHepG2cellssurvivalrateofEPI-AuNPtreatmentgroup[(43.82±2.21)%]waslowe
